NCT05225662

Brief Summary

In this study, we aimed to evaluate atrial and ventricular function in supraventricular tachyarrhythmia patients before and 3 months after RFA using 2DSTE.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2022

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 14, 2022

Completed
18 days until next milestone

Study Start

First participant enrolled

February 1, 2022

Completed
3 days until next milestone

First Posted

Study publicly available on registry

February 4, 2022

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2024

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2025

Completed
Last Updated

February 4, 2022

Status Verified

January 1, 2022

Enrollment Period

2.1 years

First QC Date

January 14, 2022

Last Update Submit

February 3, 2022

Conditions

Left Ventricular Function, Arrhythmia

Outcome Measures

Primary Outcomes (1)

  • left ventricular systolic function

    assessment of left ventricular systolic function by speckle tracking before and after radiofrequency ablation

    baseline and 3 months later

Interventions

radiofrequency ablationDIAGNOSTIC_TEST

Mesuring change in Speckle tracking analysis before and after the radiofreqency ablation

Also known as: speckle tracking

Eligibility Criteria

AgeUp to 70 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

all patient with supraventricular tachyarhythmia undergoing radiofrequency ablation

You may qualify if:

  • \- Patients with AVNRT or AVRT undergoing RF ablation

You may not qualify if:

  • \- Patient with bundle blocks
  • Coronary artery disease
  • Diastolic dysfunction ≥grade 2
  • Left ventricular hypertrophy
  • Diabetes mellitus
  • Chronic renal failure (GFR\<45ml\\min)
  • Moderate to severe valvular heart disease
  • Patient with bad echo window

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Nagai T, Hamabe A, Arakawa J, Tabata H, Nishioka T. The impact of left ventricular deformation and dyssynchrony on improvement of left ventricular ejection fraction following radiofrequency catheter ablation in Wolff-Parkinson-White syndrome: A comprehensive study by speckle tracking echocardiography. Echocardiography. 2017 Nov;34(11):1610-1616. doi: 10.1111/echo.13691. Epub 2017 Sep 19.

    PMID: 28929532BACKGROUND

  • Lelakowski J, Dreher A, Majewski J, Bednarek J, Pasowicz M. [Influence of the treatment of the atrioventricular reentry tachycardia by RF catheter ablation on the left ventricular systolic and diastolic function and exercise capacity]. Wiad Lek. 2009;62(2):71-80. Polish.

    PMID: 20141053BACKGROUND

MeSH Terms

Conditions

Arrhythmias, Cardiac

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Marwa Tantawy, master

CONTACT

01065604240drmarwatantawy7@gmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

January 14, 2022

First Posted

February 4, 2022

Study Start

February 1, 2022

Primary Completion

March 1, 2024

Study Completion

March 1, 2025

Last Updated

February 4, 2022

Record last verified: 2022-01